Navigation Links
America's Pharmaceutical Research Companies Respond to Hurricane Ike's Imminent Landfall
Date:9/12/2008

WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- Responding to conditions created by Hurricane Ike in Texas and other Gulf Coast states, the Pharmaceutical Research and Manufacturers of America (PhRMA) has moved from "alert" to "engaged" status - the highest level of activation - as part of its effort to ensure needed medicines are available in areas affected by the storm. PhRMA is working closely with other members of the RxResponse network, http://www.rxresponse.org, to provide assistance to state, local and federal emergency managers to keep the pharmaceutical supply chain open throughout areas hit by Ike.

PhRMA, along with other RxResponse Coordinating Body members, are now convening regular conference calls to manage RxResponse's efforts to coordinate requests for needed medicines and supplies, as well as other critical information about the state of the pharmaceutical supply system throughout the affected region. PhRMA is specifically coordinating with its member companies and asking them to advise the RxResponse team of Ike-related impacts on company operations, as well as to monitor and report all requests for assistance.

"We will do all we can to assist emergency managers in Texas and everyone affected by Hurricane Ike," said PhRMA President & CEO Billy Tauzin. "We are working together with key players in the pharmaceutical supply system and with emergency managers on the ground to help ensure that medicines get to the patients, hospitals and emergency evacuation centers where they are needed most."

Created following Hurricane Katrina, RxResponse is a unique business-sector effort creating a single point of contact for emergency managers and public health leaders seeking help obtaining needed medicines after a natural or man-made disaster. The RxResponse is comprised of: the American Hospital Association, the American Red Cross, the Biotechnology Industry Organization, the Generic Pharmaceutical Association, the Healthcare Distribution Management Association, the National Community Pharmacists' Association and PhRMA.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on the danger of imported drugs, visit: http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ExamForce Hires Former (ISC)2 Americas Leader to Head Corporate and Government Sales Efforts
2. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
3. DNA Find in Oregon Is Oldest Yet Discovered in Americas
4. Olympus Corporation of the Americas Names Mark Gumz President & CEO
5. Mentice, Inc. Announces Appointment of Vice-President, Sales and Marketing, Americas
6. Cochlear Americas Announces 2008 Graeme Clark Scholarship Winners
7. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
8. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
9. DSM Pharmaceutical Products Announces the Appointment of Thats Nice LLC as Agency of Record for Marketing
10. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
11. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: